Visiongain Publishes Tissue Engineering Market Report 2021-2031

10 February 2021
Pharma

Visiongain has published a new report on Tissue Engineering Market Report 2021-2031: Forecasts by Application (Cord Blood & Cell Banking, Cancer, GI & Gynaecology, Dental, Orthopaedics, Musculoskeletal, & Spine). PLUS Profiles of Leading Pharma Contract Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

Global Tissue Engineering market was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx billion by 2031. The capability of tissue engineering techniques in treating irreparable damage of tissues has boosted the market growth. Moreover, a rise in demand for reformative medicine and tissue engineering procedures to treat damaged tissues further increases this growth.

COVID-19 Impact on Tissue Engineering Market
Tissue engineering market will spur during the spread of pandemic COViD-19, as the market finds multiple application areas which includes Cord Blood & Cell Banking, Cancer, GI & Gynaecology, Dental, Orthopaedics, Musculoskeletal, & Spine which are ever-increasing areas of spread of disease.

Market Drivers

Driver 1
Tissue engineering provides substitutes to surgical reconstruction, transplants, and other automated devices that are used to repair injured tissues. The market for tissue engineering is also boosted by a constant increase in the need for effective regenerative treatments owing to a rise in the prevalence of diabetes, obesity, and other disorders due to lifestyle changes, aging population, and growing trauma cases.

Segment Analysis
Orthopaedics, musculoskeletal, and spine segment led the market for tissue engineering in 2019 due to the rise in the occurrence of musculoskeletal disorders. The orthopaedic regenerative segment includes the spine, bone substitutes, and bone grafts. According to the U.S. Medicare and Medicaid facility, there are around 900,000 surgeries every year that need bone replacement or reconstruction. The healthcare expenditure in the U.S. is increased by USD 60 billion owing to the prevalence of approximately 15 million fracture cases yearly.

Competitive Landscape
Some of the companies profiled in the market for tissue engineering include Medtronic plc; Zimmer Biomet Holdings, Inc; Allergan plc; Athersys, Inc; ACell, Inc.; Organogenesis Holdings Inc; Tissue Regenix Group plc; Stryker Corporation; RTI Surgical, Inc.; Integra Life Sciences Corporation; ReproCell, Inc.; and Baxter International, Inc.

Recent Developments
• Key players are entering into contracts and partnerships to gain a competitive advantage over their competitors. For instance, in March 2019, ACell and MyungMoon Bio Co. Ltd., signed an exclusive distribution contract for the circulation of ACell’s Cytal Wound Matrix and MicroMatrix wound management solutions in South Korea. MyungMoon is a reputed distributor and manufacturer of drugs and medical devices in South Korea.
• Additionally, major players are in a process of development of new tissue engineering products and up-gradation of their product ranges to cater the current demand. For instance, in April 2019, ACell received an additional 510(k) FDA clearance for its Gentrix product line. This headed to an increase in indications for use of the company’s Gentrix surgical matrix products.
• Besides this, companies such as Histogenics Corp.; MiMedix Group, Inc.; Genzyme; and DiscGenics have work in progress products with constructive results in preclinical and clinical trials. Anticipated successful launch of these products during the forecast period is expected to make a significant contribution towards market growth.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever